Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals (AERI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 995,901
  • Shares Outstanding, K 46,321
  • Annual Sales, $ 24,180 K
  • Annual Income, $ -232,570 K
  • 60-Month Beta 0.53
  • Price/Sales 16.32
  • Price/Cash Flow N/A
  • Price/Book 4.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.77
  • Number of Estimates 6
  • High Estimate -0.63
  • Low Estimate -0.96
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +16.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.49 +3.03%
on 01/27/20
26.26 -19.61%
on 01/09/20
-2.91 (-12.11%)
since 12/27/19
3-Month
17.15 +23.09%
on 11/21/19
26.26 -19.61%
on 01/09/20
-0.21 (-0.98%)
since 10/25/19
52-Week
17.15 +23.09%
on 11/21/19
50.10 -57.86%
on 03/21/19
-24.63 (-53.85%)
since 01/25/19

Most Recent Stories

More News
Aerie Pharmaceut Falls 2.95% on Heavy Volume: Watch For Potential Rebound

Aerie Pharmaceut (NASDAQ:AERI) traded in a range yesterday that spanned from a low of $21.62 to a high of $22.59. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of...

AERI : 21.21 (-1.35%)
Ophthalmic Therapeutic Drugs Market With Top Countries Data : Global Industry Trends, Market Size, Growth, Segmentation, Future Demands, Latest Innovation, Sales Revenue by Regional Forecast to 2025

A recent report provides crucial insights along with application based and forecast information in the The report provides a comprehensive analysis of key factors that are expected to drive the growth...

AERI : 21.21 (-1.35%)
AGN : 189.49 (+0.69%)
NVS : 93.80 (-0.07%)
REGN : 342.77 (-0.73%)
VRX.TO : 30.80 (-3.33%)
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan(R) (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with...

AERI : 21.21 (-1.35%)
Ophthalmic Therapeutic Drugs Market 2019 Global Size & Share, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2024

Get comprehensive research providing detailed regional analysis and growth outlook of the Global in the latest research report added by Big Market Research.

AERI : 21.21 (-1.35%)
AGN : 189.49 (+0.69%)
NVS : 93.80 (-0.07%)
VRX.TO : 30.80 (-3.33%)
Ophthalmic Therapeutic Drugs Market Analysed by Business Growth, Development Factors and Future Trends by 2026

Ameco Research has announced the addition of the report to their offering.

AERI : 21.21 (-1.35%)
AGN : 189.49 (+0.69%)
NVS : 93.80 (-0.07%)
REGN : 342.77 (-0.73%)
SNPHF : 19.4000 (unch)
VRX.TO : 30.80 (-3.33%)
Ophthalmic Therapeutic Drugs Market and Industry Report To 2024

Get comprehensive research providing detailed regional analysis and growth outlook of the Global in the latest research report added by Big Market Research.

AERI : 21.21 (-1.35%)
AGN : 189.49 (+0.69%)
NVS : 93.80 (-0.07%)
VRX.TO : 30.80 (-3.33%)
Latest Study: Ophthalmic Therapeutic Drugs Market Overview, Top Manufactures, Market Size, Growth Analysis & Forecast: 2019-2024

Get comprehensive research providing detailed regional analysis and growth outlook of the Global in the latest research report added by Big Market Research.

AERI : 21.21 (-1.35%)
AGN : 189.49 (+0.69%)
NVS : 93.80 (-0.07%)
VRX.TO : 30.80 (-3.33%)
Aerie's (AERI) Application for Roclanda Accepted in Europe

European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.

AGN : 189.49 (+0.69%)
PFE : 40.21 (+0.98%)
AERI : 21.21 (-1.35%)
BHC : 28.31 (-0.32%)
Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda(R) (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with...

AERI : 21.21 (-1.35%)
Look for Shares of Aerie Pharmaceut to Potentially Pullback after Yesterday's 2.65% Rise

Aerie Pharmaceut (NASDAQ:AERI) traded in a range yesterday that spanned from a low of $24.10 to a high of $24.82. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high...

AERI : 21.21 (-1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AERI with:

Business Summary

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's lead `Dual- Action` product and `Triple-Action` products are...

See More

Key Turning Points

2nd Resistance Point 23.14
1st Resistance Point 22.32
Last Price 21.21
1st Support Level 20.96
2nd Support Level 20.42

See More

52-Week High 50.10
Fibonacci 61.8% 37.51
Fibonacci 50% 33.63
Fibonacci 38.2% 29.74
Last Price 21.21
52-Week Low 17.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar